Clot Care Images
DVT Awareness | Join Our Email List | Thursday, September 02, 2010

Heart attack and stroke risks are increased in those with deep vein thrombosis (DVT) or pulmonary embolism (PE)

Henry I. Bussey, Pharm.D.
January, 2008

Danish investigators in a 20 year study evaluated the risk of myocardial infarction (MI) or stroke in 25,199 patients with deep vein thrombosis (DVT) and 16,925 patients with pulmonary embolism (PE). Compared to matched controls, those with a DVT had a 1.6 relative risk of MI and a 2.19 relative risk of a stroke within the first year after the DVT. For those with a PE, the relative risk for MI was 2.60 and for stroke was 2.93 within the first year. The risk persisted for the remainder of the 20 year study but was considerably lower with a 20% to 40% increase. Interestingly, whether the DVT or PE was provoked or unprovoked did not seem to make a difference. Whether there is a cause and effect relationship between DVT or PE and arterial events or whether the events simply reflect the presence of underlying risk factors for both conditions was not determined in this trial. Further, whether DVT and PE patients would benefit from prolonged antiplatelet, anticoagulant, and/or statin therapies are issues that warrant further study.

For a more thorough discussion of this article and the accompanying editorial, you may go to http://www.theheart.org/article/829429.do or may review the original publications at:

  1. Sorensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalization due to acute cardiovascular events: a 20-year cohort study. Lancet 2007; 370:1773-1779.

  2. Lowe GD. Is venous thromboembolism a risk factor for arterial thrombosis? Lancet 2007; 370:1742-1744.
Copyright 2000-2010 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
Send comments to webmaster@clotcare.org.
ClotCare is a charitable 501(c)(3) non-profit organization. Click here to donate.
ClotCare Online Resource covers topics such as Coumadin, warfarin, blood clot, stroke, heart attack, INR, PT, low molecular weight haparin, heparin, dvt, anticoagulation, antithrombotic therapy, A. fib, atrial fibrillation, heart valve, heart valve replacement, vitamin k, AstraZeneca, Aventis, CE credit, and more.